Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Patient demographics

From: The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial

Patient characteristic

Total

Fluoxetine

Placebo

P-value*

 

N = 34 (100%)

N = 18 (53%)

N = 16 (47%)

 

Ethnicity, n (%)

   

.75

White

25 (73%)

14 (78%)

11 (19%)

 

African American

6 (18%)

3 (17%)

3 (69%)

 

Other

3 (9%)

1 (5%)

2 (12%)

 

Age (years), mean ± SD

16.46 ± 1.08

16.55 ± 1.11

16.35 ± 1.08

.61

Gender, n (%)

   

.18

Female

5 (15%)

4 (22%)

1 (6%)

 

Male

29 (85%)

14 (78%)

15 (94%)

 

Current Depressive Disorder

MDDa

29 (85.3%)

15 (83.3%)

14 (87.5%)

1.0

Other Depressive Disorderb

5 (14.7%)

3 (16.7%)

2 (12.5%)

.56

Age at onset of depression, mean ± SD

11.41 ± 2.5

11.9 ± 2.7

10.8 ± 2.1

.19

Length of depression, mean ± SD (weeks)

213.1 ± 153.6

185.0 ± 168.3

244.7 ± 133.4

.26

Current comorbid condition, n (%)

ADHDc

11 (32.4%)

6 (33%)

5 (31.3%)

1.0

Post Traumatic Stress Disorder

2 (5.9%)

1 (5.6%)

1 (6.3%)

1.0

Conduct Disorder

2 (5.9%)

0 (0%)

2 (12.5%)

.21

Current SUD d,e

Alcohol

13 (38.2%)

7 (38.9%)

6 (37.5)

1.0

Alcohol Abuse

10 (29.4%)

5 (27.8%)

5 (31.25%)

1.0

Alcohol Dependence

3 (8.8%)

2 (11.1%)

1 (6.25%)

 

Cannabis

30 (88.2%)

15 (83.3%)

15 (93.8%)

.60

Cannabis Abuse

16 (47%)

9 (50.0%)

7 (43.8%)

.72

Cannabis Dependence

14 (41.2%)

6 (33.3%)

8 (50.0%)

 

Polysubstance

1 (2.9%)

0 (0%)

1 (6.3%)

.47

Age at onset of SUD e , mean ± SD

13.7 ± 1.2

13.8 ± 1.3

13.7 ± 1.3

.86

Length of SUD, mean ± SD (weeks)

117.4 ± 68.7

116.0 ± 72.4

118.9 ± 66.8

.91

  1. aMajor Depressive Disorder; 2 patients with MDD had a comorbid Dysthymic disorder diagnosis
  2. b4 patients were diagnosed with Dysthymic Disorder, 3 patients had Depression Not Otherwise Specified
  3. cAttention Deficit/Hyperactivity Disorder
  4. dSubstance Use Disorder
  5. e10 patients had more than one substance use disorder
  6. *Fisher's exact test analyses were used to compare percentages; generalized linear model (GLM) procedures were used for comparisons of continuous variables between treatment groups
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000